A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA (BORA)
A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)
Sponsor: AstraZeneca
A PHASE3 clinical study on Asthma, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 17 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE3
▶ Show 12 earlier versions
-
Dec 2021 — Jan 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2019 — Sep 2020 [monthly]
Completed PHASE3
-
Mar 2019 — Sep 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Mar 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .